Press Releases

Date	Title
October 7, 2020	Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital MONMOUTH JUNCTION, N.J. , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence
September 30, 2020	Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration MONMOUTH JUNCTION, N.J. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) is a late clinical-stage biopharmaceutical company developing the first FDA-approved ophthalmic formulation of bevacizumab-vikg (LYTENAVA™) for use in retinal indications (known as ONS-5010).
September 8, 2020	Outlook Therapeutics to Present at Two Upcoming Investor Conferences MONMOUTH JUNCTION, N.J. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence
August 26, 2020	Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) from NORSE 1 ONS-5010, an investigational ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD, demonstrated safety and efficacy profile consistent with previously published ophthalmic bevacizumab research NORSE 1 results support trial design and inclusion criteria for fully enrolled, ongoing
August 14, 2020	Outlook Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2020 and Provides Corporate Update Successfully completed NORSE 2 enrollment in July 2020 NORSE 1 topline results to be reported in August 2020 MONMOUTH JUNCTION, N.J. , Aug. 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first
July 17, 2020	Outlook Therapeutics Announces Closing of $1.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules MONMOUTH JUNCTION, N.J. , July 17, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the successful
July 7, 2020	Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Pivotal NORSE 2 safety and efficacy data expected to be reported in the third calendar quarter of 2021 ONS-5010 / LYTENAVA ™ (bevacizumab-vikg) has the potential to be the first FDA-approved ophthalmic formulation of bevacizumab for use in multiple retinal indications MONMOUTH JUNCTION, N.J.
June 25, 2020	Outlook Therapeutics Announces Closing of $10.2 Million Financing Priced At-The-Market Under Nasdaq Rules MONMOUTH JUNCTION, N.J. , June 25, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“the Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that
June 23, 2020	Outlook Therapeutics Announces $11.2 Million Financings Priced At-The-Market Under Nasdaq Rules MONMOUTH JUNCTION, N.J. , June 23, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“the Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that
June 17, 2020	Outlook Therapeutics Provides Clinical Update on ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Lead product candidate ONS-5010 / LYTENAVA TM (bevacizumab-vikg) has potential to be first FDA-approved ophthalmic formulation of bevacizumab for use in multiple retinal indications Topline results from NORSE 1, the Company’s first registration clinical trial evaluating ONS-5010 and providing